Search
Tvardi Therapeutics Ord Shs
TVRDAdd to Watchlist
2.350USD
-0.070-2.89%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
22.05MMarket Cap
0.36P/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
9
analysts
Buy
Current Rating
8.286
Target Price
+215.05%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Tvardi Therapeutics Ord Shs
TVRD
9
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Tvardi Therapeutics Ord Shs's price target?
Analysts forecast that Tvardi Therapeutics Ord Shs's price target is USD 10.00, with the highest forecast at USD 52.00 and the lowest forecast at USD 4.00.
How have Tvardi Therapeutics Ord ShsTVRD's recent earnings per share performed?
The market expectation was USD -0.73, while Tvardi Therapeutics Ord ShsTVRD's earnings per share (EPS) for the previous quarter was USD -0.77. EPS for the next quarter is expected at USD -0.70.
What is the analyst rating for Tvardi Therapeutics Ord Shs?
Based on the ratings of Tvardi Therapeutics Ord Shs's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
